Would you offer gemcitabine/cisplatin (or other platinum-based regimens) for metastatic pancreatic cancer harboring somatic ATM mutations?
NCCN indicates only BRCA1/2 and PALB2 mutations.
1 Answer
Mednet Member
Medical Oncology · St. Vincent's Medical Center
Answered on
Yes, potential sensitivity to DNA-damaging agents.
Join for free or sign in to see the full answer